GlassScriptPhysician profile
Nona Cunningham
NPI 1770560997
$4,587.44
in general payments reported to CMS, 2019-2025
34 companies · $421 in 2025
The $421 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $584 · 2021: $835 · 2022: $635 · 2023: $782 · 2024: $673 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.04 |
| Education | $185.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,002.91 | 2021-2025 | |
| Abbvie INC. | $613.89 | 2019-2025 | Lo Loestrin Fe |
| Astellas Pharma US INC | $432.13 | 2022-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $392.37 | 2019-2022 | |
| Organon LLC | $348.49 | 2021-2025 | Nexplanon |
| Avion Pharmaceuticals | $216.36 | 2019-2022 | |
| Myovant Sciences INC. | $176.72 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $171.61 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $165.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.06 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $140.93 | 2019 | |
| Merck Sharp & Dohme LLC | $113.34 | 2019-2021 | |
| Shield Therapeutics INC | $86.66 | 2023-2025 | Accrufer |
| Lupin INC. | $80.18 | 2019-2020 | |
| Ethicon US, LLC | $73.76 | 2019-2025 | Stratafix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $36.17 | 2020-2021 | |
| Pfizer INC. | $35.41 | 2019-2022 | |
| Evofem Biosciences, INC. | $33.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $26.68 | 2025 | |
| Zyla Life Sciences, INC. | $26.40 | 2020 | |
| Sumitomo Pharma America, INC. | $26.25 | 2023 | Myfembree |
| Dexcom, INC. | $25.44 | 2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $25.35 | 2025 | Zurzuvae |
| Tersera Therapeutics LLC | $24.89 | 2023 | Quzyttir |
| Daiichi Sankyo INC. | $24.76 | 2019 | |
| Exact Sciences Corporation | $19.20 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $18.60 | 2020 | |
| Dysis Medical, INC. | $18.51 | 2022 | |
| Agile Therapeutics, INC. | $18.00 | 2021 | |
| Millicent US INC | $16.22 | 2025 | Femlyv |
| Mylan Pharmaceuticals INC. | $14.95 | 2020 | |
| Aspira Women'S Health INC | $14.48 | 2022 | |
| Hologic Sales and Service, LLC | $13.04 | 2019 | |
| Coopersurgical, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nona Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.